Aligos Therapeutics, Inc. (NASDAQ:ALGS – Free Report) – Analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($2.37) per share for the quarter, down from their previous estimate of ($1.85). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2025 earnings at ($2.35) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at $5.91 EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($8.97) EPS, FY2027 earnings at ($9.99) EPS, FY2028 earnings at ($9.24) EPS and FY2029 earnings at ($9.12) EPS.
Aligos Therapeutics Price Performance
Aligos Therapeutics stock opened at $10.81 on Thursday. The firm has a market capitalization of $38.79 million, a PE ratio of -0.81 and a beta of 2.52. The company’s 50-day moving average is $25.48 and its 200-day moving average is $20.46. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $46.80.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its stake in shares of Aligos Therapeutics by 48.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 325,000 shares of the company’s stock worth $12,948,000 after purchasing an additional 106,187 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Aligos Therapeutics during the 4th quarter worth about $2,751,000. Avantax Advisory Services Inc. bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth about $1,218,000. Geode Capital Management LLC boosted its holdings in shares of Aligos Therapeutics by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company’s stock worth $1,086,000 after buying an additional 3,197 shares during the period. Finally, Drive Wealth Management LLC bought a new stake in shares of Aligos Therapeutics during the 4th quarter worth about $916,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Stories
- Five stocks we like better than Aligos Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- How to Use Stock Screeners to Find Stocks
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Profitably Trade Stocks at 52-Week Highs
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.